• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ConforMIS, Inc.

    6/14/21 4:49:59 PM ET
    $CFMS
    Industrial Specialties
    Health Care
    Get the next $CFMS alert in real time by email
    SC 13G 1 conformisinc13g.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Conformis, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

    20717E101

    (CUSIP Number)

     

     

    June 8, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 20717E101

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 9,161,871

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 9,161,871
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 9,161,871

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.0%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 20717E101

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 9,161,871

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 9,161,871
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 9,161,871

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 20717E101

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 9,161,871

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 9,161,871
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 9,161,871

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 20717E101

     

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 9,161,871

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 9,161,871
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 9,161,871

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     5 
    CUSIP No. 20717E101

     

    Item 1.

     

    (a)Name of Issuer

    Conformis, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    600 Technology Park Drive, Billerica, MA 01821

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703-2767

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.00001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 20717E101

     

     6 
    CUSIP No. 20717E101
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     7 
    CUSIP No. 20717E101

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 20717E101

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 14, 2021

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: _/s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

     9 
    CUSIP No. 20717E101

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

     

    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS

    DatePrice TargetRatingAnalyst
    11/4/2021$2.50 → $2.00Outperform
    Oppenheimer
    9/22/2021$3.00 → $2.50Outperform
    Oppenheimer
    More analyst ratings

    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:51 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:47 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously

      11/4/21 10:00:09 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously

      9/22/21 7:20:22 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • restor3d Completes Acquisition of Conformis

      DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

      9/5/23 8:18:31 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

      8/23/23 8:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

      8/21/23 4:10:25 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      7/10/23 5:14:02 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/14/23 12:20:12 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/13/23 10:56:02 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Financials

    Live finance-specific insights

    See more
    • Conformis Reports First Quarter 2023 Financial Results

      BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

      5/8/23 8:05:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

      BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

      4/13/23 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

      BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

      3/1/23 4:05:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

      BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

      4/1/22 5:00:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

      BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

      3/14/22 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

      BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

      11/8/21 9:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Conformis Inc.

      15-12G - Conformis Inc (0001305773) (Filer)

      9/15/23 9:56:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:15 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:13 AM ET
      $CFMS
      Industrial Specialties
      Health Care